Showing results (271-280 of 542) with videos related to
Sort By:
Pageof 55
ESMO Open|November 16, 2016
Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trialSalvatore Siena, Josep Tabernero, Gyorgy Bodoky, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2018
A Multicenter Phase II Study of AMG 337 in Patients with MET-Amplified Gastric/Gastroesophageal Junction/Esophageal Adenocarcinoma and Other MET-Amplified Solid TumorsEric Van Cutsem, Boguslawa Karaszewska, Yoon-Koo Kang, et al.BMC Hematology|August 22, 2018
Rapid access clinic for unexplained lymphadenopathy and suspected malignancy: prospective analysis of 1000 patientsAndrea Kühnl, David Cunningham, Margaret Hutka, et al.British Journal of Cancer|December 20, 2023
Stroma AReactive Invasion Front Areas (SARIFA) improves prognostic risk stratification of perioperative chemotherapy treated oesophagogastric cancer patients from the MAGIC and the ST03 trialBianca Grosser, Jake Emmerson, Nic G Reitsam, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2006
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancerIan Chau, Gina Brown, David Cunningham, et al.Frontiers in Neuroscience|February 19, 2026
Evaluation of the myogenic effects of subthalamic nucleus deep brain stimulation at near therapeutic amplitudesCarmen Toth, Brett A Campbell, Leonardo Favi Bocca, et al.Cancer Treatment Reviews|April 12, 2020
Imaging and clinical correlates with regorafenib in metastatic colorectal cancerKhurum Khan, Stefano Cascinu, David Cunningham, et al.The Lancet. Oncology|September 14, 2013
Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trialDavid Cunningham, Istvan Lang, Eugenio Marcuello, et al.JAMA Oncology|May 26, 2018
Assessment of a Noninvasive Exhaled Breath Test for the Diagnosis of Oesophagogastric CancerSheraz R Markar, Tom Wiggins, Stefan Antonowicz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2002
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331Hugo E R Ford, Fraser Mitchell, David Cunningham, et al.Pageof 55